Vanguard Group Inc. Has $114.38 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. $TARS

Key Points

• Vanguard Group Inc. increased its stake in Tarsus Pharmaceuticals by 5.3%, owning 2,226,595 shares valued at $114.38 million as of its latest SEC filing.
• Several institutional investors have also significantly increased their positions in Tarsus, with Price T Rowe Associates lifting its stake by 92.5% during the fourth quarter.
• Wall Street analysts are optimistic, with target price upgrades from firms like Goldman Sachs and Oppenheimer, indicating a consensus rating of "Buy" for Tarsus Pharmaceuticals.

Vanguard Group Inc. boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,226,595 shares of the company's stock after acquiring an additional 111,433 shares during the period. Vanguard Group Inc. owned 5.30% of Tarsus Pharmaceuticals worth $114,380,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in TARS. Amalgamated Bank increased its stake in Tarsus Pharmaceuticals by 30.1% during the first quarter. Amalgamated Bank now owns 1,274 shares of the company's stock valued at $65,000 after purchasing an additional 295 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Tarsus Pharmaceuticals by 12.6% in the 4th quarter. Northern Trust Corp now owns 357,616 shares of the company's stock valued at $19,801,000 after buying an additional 40,061 shares during the period. GAMMA Investing LLC grew its position in shares of Tarsus Pharmaceuticals by 36,430.6% during the 1st quarter. GAMMA Investing LLC now owns 13,151 shares of the company's stock valued at $676,000 after buying an additional 13,115 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Tarsus Pharmaceuticals by 21.2% during the fourth quarter. Ameriprise Financial Inc. now owns 47,685 shares of the company's stock worth $2,640,000 after acquiring an additional 8,336 shares during the period. Finally, Rhumbline Advisers raised its stake in Tarsus Pharmaceuticals by 4.3% during the first quarter. Rhumbline Advisers now owns 51,682 shares of the company's stock worth $2,655,000 after acquiring an additional 2,148 shares during the period. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ:TARS traded up $0.69 on Friday, hitting $57.25. The company's stock had a trading volume of 615,773 shares, compared to its average volume of 729,781. The company has a market capitalization of $2.42 billion, a price-to-earnings ratio of -24.57 and a beta of 0.79. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.21 and a current ratio of 5.26. Tarsus Pharmaceuticals, Inc. has a 12 month low of $25.19 and a 12 month high of $57.60. The stock's 50-day moving average is $43.84 and its two-hundred day moving average is $45.79.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.15). The company had revenue of $102.66 million during the quarter, compared to analyst estimates of $95.81 million. Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%. On average, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Wall Street Analyst Weigh In

TARS has been the topic of a number of research reports. The Goldman Sachs Group increased their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. HC Wainwright upgraded Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price objective for the company in a research note on Tuesday, May 27th. Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Guggenheim boosted their price target on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Finally, Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals in a report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $66.67.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of the company's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $50.00, for a total value of $300,000.00. Following the completion of the sale, the chief executive officer directly owned 818,106 shares in the company, valued at $40,905,300. This represents a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.97% of the stock is currently owned by insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.